Premium
Eslicarbazepine acetate as adjunctive treatment in partial‐onset epilepsy
Author(s) -
Lattanzi S.,
Cagnetti C.,
Foschi N.,
Lorusso A.,
Provinciali L.,
Silvestrini M.
Publication year - 2018
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/ane.12803
Subject(s) - medicine , carbamazepine , oxcarbazepine , adverse effect , somnolence , epilepsy , nausea , concomitant , cohort , hazard ratio , clinical endpoint , partial seizures , anesthesia , confidence interval , randomized controlled trial , psychiatry
Objective The aim of the study was to assess the clinical response to eslicarbazepine acetate ( ESL ) as add‐on therapy in adult patients with partial‐onset epilepsy by means of the time‐to‐baseline seizure count method. Methods We retrospectively identified consecutive patients with partial‐onset seizures, with or without secondary generalization, prescribed to ESL add‐on therapy. The primary endpoint was the time‐to‐baseline monthly seizure count. Subgroup analysis was performed according to carbamazepine ( CBZ )/oxcarbazepine ( OXC ) status ( prior vs never use). Secondary outcomes were the rate of treatment‐related adverse events ( AE s) and the AE s affecting ≥5% of patients. Results One‐hundred and eighteen patients were included. The median time‐to‐baseline monthly seizure count was 46 (35‐101) days in the overall study cohort. The number of concomitant anti‐epileptic drugs ( AED s) was associated with the time‐to‐endpoint (adjusted hazard ratio [ adj HR ]=2.22, 95% CI 1.18‐4.14, P =.013 for two AED s vs one; adj HR =3.65, 95% CI 1.66‐8.06, P =.001 for three or more AED s vs one). Groupwise, the median times‐to‐baseline seizure count were 47 (35‐97) and 43 (34‐103) in patients with prior and never exposure to CBZ / OXC , respectively ( P for log‐rank test=.807). Adverse events occurred in 53.4% (63 of 118) of patients; the most frequently reported were dizziness (13.6%), somnolence (11.9%), nausea (6.8%), and fatigue (5.1%). Conclusions Add‐on ESL improved seizure control and was overall well‐tolerated in adult patients with partial‐onset epilepsy.